Tech Company Financing Transactions

Adagio Therapeutics Funding Round

On 11/11/2020, Adagio Therapeutics received $80 million in Series B funding from GV, Fidelity Management & Research Company and Mithril Capital Management.

Transaction Overview

Company Information

Company Status

Publicly-held

Industry

Biopharmaceutical

Mailing Address

303 Wyman St. 300
Waltham, MA 02451
USA

Phone

Undisclosed

Website

www.adagiotx.com

Email Address

[email protected]

Overview

Adagio is developing best-in-class antibodies that can broadly neutralize SARS-CoV-2, SARS-CoV-1 and additional potentially emergent coronaviruses. We believe our antibodies will match or exceed the potency and coverage of conventional SARS-CoV-2 antibody programs, and can be used as both therapeutic and durable prophylactic treatments.

Profile

Social Media

Company News

Facebook

YouTube

Management Team

Title

Name

Email & Social

Chief Executive Officer

Tillman Gerngross

        

Chief Financial Officer

Jane Henderson

        

Chief Medical Officer

Lynn Connolly

        

Chief Operating Officer

Halley Gilbert

        

Chief Scientific Officer

Laura Walker

        

Chief Technical Officer

Becky Dabora

        

VP - Bus. Development

Ellie Hershberger

        

VP - Bus. Development

Eric Kimble

        

Browse more venture capital transactions:

Prev: 11/11/2020: Tailscale venture capital transaction
Next: 11/11/2020: Explo venture capital transaction

Share this article

About Database of VC Transactions

We do our best to report on all VC transactions involving tech companies. VC investment data records reported here are sourced from a variety of public sources. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.

Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary